Challenges and opportunities in stewardship among solid organ transplant recipients with Candida auris bloodstream infections

Abstract

Background Candida auris is an emerging nosocomial pathogen worldwide. However, there has been little published on the management of C. auris in solid organ transplant recipients. Methods A single‐center, retrospective cohort study was conducted to evaluate C. auris bloodstream infections in solid organ transplant recipients between January 2020 and December 2021. Patient‐related and outcomes data were extracted from electronic medical records. Results Of the 42 patients identified with C. auris bloodstream infections, five were in solid organ transplant recipients (1 heart, 3 liver, and 1 combined liver‐kidney). The median time to fungemia from hospital admission was 43 days, and the median time to fungemia from transplant was 18 days. All patients received micafungin as initial treatment, at a median of 6 hours from pathogen detection. Four patients achieved blood clearance, two patients had persistent fungemia, and two patients developed secondary complications from hematogenous spread. One patient died, resulting in a mortality rate of 20%. Conclusions Solid organ transplant recipients are at high risk for developing C. auris bloodstream infections. In order to prevent graft loss and mortality, best practices for the management of C.auris should include rapid screening, diagnosis, and treatment. While echinocandins are considered first‐line, antifungal selection should be based on susceptibilities and site of infection. Data to support routine use of combination therapy are lacking, however there may be a role for refractory cases. Prevention efforts against C. auris infection are especially important given the lack of effective decolonization strategies. For transplant recipients, hospitals should seek opportunities to restore patients' gut microbiome by curtailing unnecessary hospital procedures and inappropriate antimicrobial use. Further research and national guidelines are needed to better direct stewardship in this field.

Intestinal colonization with Candida auris and mucosal immune response in mice treated with cefoperazone oral antibiotic

“…C. auris was recently identified as one of the major Candida species in patients all over the world. Major risk factors for invasive C. auris infections include solid organ transplantation, diabetes, chronic kidney disease and prior antibiotic use ( 4 , 6 , 38 ). The colonization and host immune response to C. auris in different host niches is still not clear.…”

Candida auris and new concern in clinical surgery

“…[4] The choice of an antifungal should be made based on susceptibilities and the site of infection, even if echinocandins are thought of as first-line agents. [4] According to an Indian study, patients with C. auris candidemia had a greater crude death rate than those with other species. [5] In order to rebuild the gut microbiome of transplant recipients, hospitals should, according to Vu et al, reduce the use of unsuitable antimicrobials and needless hospital procedures.…”

“…[5] In order to rebuild the gut microbiome of transplant recipients, hospitals should, according to Vu et al, reduce the use of unsuitable antimicrobials and needless hospital procedures. [4]…”

“…[4] On the management of C. auris in recipients of solid organ transplants, however, not much has been written. [4] Solid organ transplant recipients have a high risk of contracting C. auris bloodstream infections, according to Vu et al Best practices for the management of C. auris should involve quick screening, diagnosis, and treatment in order to avoid graft loss and mortality. [4] The choice of an antifungal should be made based on susceptibilities and the site of infection, even if echinocandins are thought of as first-line agents.…”

“…[4] Solid organ transplant recipients have a high risk of contracting C. auris bloodstream infections, according to Vu et al Best practices for the management of C. auris should involve quick screening, diagnosis, and treatment in order to avoid graft loss and mortality. [4] The choice of an antifungal should be made based on susceptibilities and the site of infection, even if echinocandins are thought of as first-line agents. [4] According to an Indian study, patients with C. auris candidemia had a greater crude death rate than those with other species.…”